This activity was originally presented as part of the 2024 Asembia Specialty Day of Education Winter Edition.
Program Description
Primary biliary cholangitis (PBC) is a rare, chronic, progressive autoimmune liver disease. Advances in disease awareness, diagnostic assays for AMA detection, and routine liver function tests have improved the diagnosis of cholestasis. Current treatment options for PBC are not curative and have been associated with adverse effects including fatigue and pruritus that remain burdensome for patients. Itch due to PBC remains undertreated, with just 50% of patients receiving treatment. This session will explore recent clinical data for new and emerging therapies under investigation for the treatment of cholestatic pruritus, with an emphasis on the role of specialty pharmacists in diagnosis, treatment decision-making, and monitoring of adverse effects in patients with PBC. Specialty pharmacists will be able to apply patient-focused interventions, such as educating patients on proper treatment use and administration, identifying patients who may benefit from alternative treatments, and assisting patients with accessing approved treatment options in their roles with managing PBC and associated pruritus.
Target Audience: Specialty pharmacists
Type of Activity: Application
Release date: December 19, 2024
Expiration date: December 19, 2025
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the burden of illness associated with primary biliary cholangitis (PBC), including the significant impact of pruritus and fatigue on patients' quality of life
- Analyze current and potential novel therapies for cholestatic pruritus, considering their mechanism of action, efficacy data, and safety profile, to inform patient care decisions
- Identify pharmacist-led interventions to improve clinical outcomes and alleviate symptoms in patients with PBC
Anastasia Abramson, PharmD, MBA
Manager of Clinical Strategy and Patient Engagement
PANTHERx Rare Pharmacy
Pittsburgh, Pennsylvania
Linda M. Spooner, PharmD, BCPS, FASHP, FCCP
Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences (MCPHS) University
School of Pharmacy-Worcester/Manchester
Worcester, Massachusetts
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-346-H01-P. The activity is available for CE credit through December 19, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Anastasia Abramson, PharmD, MBA
Linda M. Spooner, PharmD, BCPS, FASHP, FCCP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Aleksandra Thomas; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here